John Crispino - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock John Crispino's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
John Crispino
Verified
Member, St. Jude Faculty and Editorial Board Member, Blood Cancer Journal
Beats
Retail,Smartphones Food, Wearables AI, Automotive Consumer Technology, Health Tech Events & Experiences
Food and drink.
Content
By John Crispino| Wiley Online Library Verified Use the link below to share a full-text version of this article with your friends and colleagues. Learn more. I have read and accept the Wiley Online Library Terms and Conditions of UseI have read and accept the Wiley Online Library Terms and Conditions of UseJ.D.C. is an advisor to Alethiomics and receives research funding from Syndax. The other author declares no conflicts of interest. No abstract is available for this article.
DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition - Leukemia
By Srividya Swaminathan, Christian Hurtz, Rahul S Bhansali, Wayne E. Childers, Thomas A. Milne, Kathrin Bernt, Thierry Besson, Junwei Shi, John Crispino, Sarah Tasian| Nature Verified AbstractUnbiased kinome-wide CRISPR screening identified DYRK1A as a potential therapeutic target in KMT2A-rearranged (KMT2A-R) B-acute lymphoblastic leukemia (ALL). Mechanistically, we demonstrate that DYRK1A is regulated by the KMT2A fusion protein and affects cell proliferation by regulating MYC expression and ERK phosphorylation.
By John Crispino| Wiley Online Library Verified Use the link below to share a full-text version of this article with your friends and colleagues. Learn more. I have read and accept the Wiley Online Library Terms and Conditions of UseI have read and accept the Wiley Online Library Terms and Conditions of UseJ.D.C. is an advisor to Alethiomics and receives research funding from Syndax. The other author declares no conflicts of interest. No abstract is available for this article.
Company Info
Blood Cancer Journal
Memphis, Tennessee, United States
+1 888-226-4343